Genentech obtains expanded FDA approval of eye drug Lucentis

06/23/2010 | Google

Genentech received FDA approval to promote Lucentis as a treatment for macular edema, a condition that can lead to blindness because of blockage in retinal veins. The drug was approved in 2006 to treat patients with "wet" age-related macular degeneration.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL